Commercialization of Pharmaceutical Products in the USA (Color)

Front Cover
RxCommercial Research International Inc.
RxCommercial, Aug 18, 2011
 

What people are saying - Write a review

We haven't found any reviews in the usual places.

Contents

BioPharma Industry Overview
1
BioPharma Model
19
Product Value Creation outlines product life cycle management strategies that
21
4C1 3
67
OptimizeChanelMixforEachStakeholderGroup
73
BioPharma RD Spend versus Number of NMEs Approved
80
Product Value
89
Relative Stakeholder Perceptions For Illustration Only
98
Overview ofa typical quality risk management process
148
Role ofGPOs in Product Procurement
161
Distribution of New Products
174
Role of Medicines in the Overall Promise and Success ofthe BioPharma Industry
191
Figure 4C2 6 MCOs Role in Providing Coverage
200
ProductValueCreation
235
The best approach to manage RD portfolio commences with reviewing the existing one Fig
266
InnovativeMedicines
277

Different Options of Pricing Strategy for Highly Differentiated orme toodrugs
105
Example of Payment for a Drug with AWP of 100
111
Product Revenue Forecast Scenarios For Illustration Only
121
Options to Deal with Uncertainties For Illustration Only
129
Product Commercialization
133
Risk Assessment
147
Abbreviations
279
11
283
Development Model
284
References
289
Copyright

Other editions - View all

Common terms and phrases

About the author (2011)

RxCommercial Research International offers “innovative and practical solutions to commercializing life sciences products” around the world. The firm’s products range from commercialization solutions to investment research designed to empower pharmaceutical, biotechnology, and medical device companies to maximize their commercial investments. These products are made available in most international languages. For additional information on the below products, please visit www.RxCommercial.com.

Bibliographic information